Virion host shutoff (vhs)-deficient herpes simplex virus (HSV) was tested as a therapeutic vaccine in a mouse model of UV light-induced recurrent herpetic stromal keratitis. Four weeks after primary corneal infection, mice were vaccinated intraperitoneally with vhs− vaccine or control. Four weeks after vaccination, the eyes of latently infected mice were UV-B irradiated to induce recurrent virus shedding and disease. Post-irradiation corneal opacity in latently infected, vhs−-vaccinated mice was significantly reduced compared to control-vaccinated mice (P=0·007 to 0·035). The incidence and duration of recurrent virus shedding were the same in both groups. Antibody titres were increased (P=0·05) and delayed type hypersensitive responses were unaffected by vhs− vaccination. Combined with studies using different vaccination timing and vhs− genotypes, these data suggest that deletion of vhs is a useful strategy in the development of a therapeutic HSV vaccine, and that temporal and genetic factors influence vaccination outcome.
BrubakerJ. O.,
ThompsonC. M.,
MorrisonL. A.,
KnipeD. M.,
SiberG. R.,
FinbergR. W.1996; Induction of Th1-associated immune responses to beta-galactosidase expressed by a replication-defective mutant of herpes simplex virus 1. Journal of Immunology 157:1598–1604
DaheshiaM.,
KuklinN.,
KannangatS.,
ManickanE.,
RouseB. T.1997; Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. Journal of Immunology 159:1945–1952
DeshpandeS. P.,
KumaraguruU.,
RouseB. T.2000; Why do we lack an effective vaccine against herpes simplex virus infections?. Microbes and Infection 2:973–978
GeissB. J.,
SmithT. J.,
LeibD. A.,
MorrisonL. A.2000; Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain. Journal of Virology 74:11137–11144
KeadleT. L.,
LaycockK. A.,
MillerJ. K.,
HookK. K.,
FenoglioE. D.,
FrancotteM.,
SlaouiM.,
StuartP. M.,
PeposeJ. S.1997; Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice. Journal of Infectious Diseases 176:331–338
KwongA. D.,
FrenkelN.1987; Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proceedings of the National Academy of Sciences, USA 84. 1926-1930
LaycockK. A.,
LeeS. F.,
BradyR. H.,
PeposeJ. S.1991; Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultra violet B radiation. Investigative Ophthalmology & Visual Science 32:2741–2746
LiuT.,
KhannaK. M.,
ChenX.,
FinkD. J.,
HendricksR. L.2000; CD8+ T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. Journal of Experimental Medicine 191:1459–1466
MillerJ. K.,
LaycockK. A.,
UmphressJ. A.,
HookK. K.,
StuartP. M.,
PeposeJ. S.1996; A comparison of recurrent and primary herpes simplex keratitis in NIH inbred mice. Cornea 15:497–504
PeposeJ. S.,
LeibD. A.,
StuartP. M.,
EastyE. L.1996; Herpes simplex virus diseases: anterior segment of the eye. In Ocular Infection and Immunity pp 905–932 Edited by
PeposeJ. S.,
HollandG. A. N.,
WilhelmusK. R.
St Louis, MO: Mosby;
RussellR. G.,
NasisseM. P.,
LarsenH. S.,
RouseB. T.1984; Role of T-lymphocytes in the pathogenesis of herpetic stromal keratitis. Investigative Ophthalmology & Visual Science 25:938–944
ShimeldC.,
HillT.,
BlythW. A.,
EastyD. L.1990; Passive immunization protects the mouse eye from damage after herpes simplex virus infection by limiting spread of virus in the nervous system. Journal of General Virology 71:681–687
StrelowL. I.,
LeibD. A.1995; Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. Journal of Virology 69:6779–6786
StumpfT. H.,
ShimeldC.,
EastyD. L.,
HillT. J.2001; Cytokine production in a murine model of recurrent herpetic stromal keratitis. Investigative Ophthalmology & Visual Science 42:372–378
TiggesM. A.,
LengS.,
JohnsonD. C.,
BurkeR. L.1996; Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2 infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. Journal of Immunology 156:3901–3910
TumpeyT. M.,
ElnerV. M.,
ChenS.,
OakesJ. E.,
LauschR. N.1994; Interleukin-10 treatment can suppress stromal keratitis induced by herpes simplex virus type 1. Journal of Immunology 153:2258–2265
WalkerJ.,
LeibD. A.1998; Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in virion host shutoff (vhs) function. Vaccine 16:1–5